WO2016040767A3 - Chrdl-1 epitopes and antibodies - Google Patents

Chrdl-1 epitopes and antibodies Download PDF

Info

Publication number
WO2016040767A3
WO2016040767A3 PCT/US2015/049622 US2015049622W WO2016040767A3 WO 2016040767 A3 WO2016040767 A3 WO 2016040767A3 US 2015049622 W US2015049622 W US 2015049622W WO 2016040767 A3 WO2016040767 A3 WO 2016040767A3
Authority
WO
WIPO (PCT)
Prior art keywords
chrdl
fragments
derivatives
antibodies
antigen binding
Prior art date
Application number
PCT/US2015/049622
Other languages
French (fr)
Other versions
WO2016040767A2 (en
Inventor
Kevin Christopher Corbit
Christopher J.R. Paszty
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of WO2016040767A2 publication Critical patent/WO2016040767A2/en
Publication of WO2016040767A3 publication Critical patent/WO2016040767A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention provides compositions and methods relating to or derived from antigen binding proteins to CHRDL-1. Human, humanized, and chimeric antibodies, as well as fragments and derivatives thereof are further contemplated where such antibodies are defined as selectively binding to CHRDL-1 in particular regions of the protein that result in neutralization and thereby treatment of disorders associated with CHRDL-1 expression. Other embodiments include nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, as well as polypeptides, cells, methods of making and using antigen binding proteins, fragments and derivatives thereof.
PCT/US2015/049622 2014-09-12 2015-09-11 Chrdl-1 epitopes and antibodies WO2016040767A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049975P 2014-09-12 2014-09-12
US62/049,975 2014-09-12

Publications (2)

Publication Number Publication Date
WO2016040767A2 WO2016040767A2 (en) 2016-03-17
WO2016040767A3 true WO2016040767A3 (en) 2016-04-28

Family

ID=54150742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/049622 WO2016040767A2 (en) 2014-09-12 2015-09-11 Chrdl-1 epitopes and antibodies

Country Status (1)

Country Link
WO (1) WO2016040767A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220129044A (en) * 2020-01-16 2022-09-22 카이로스 테라퓨틱스 인코포레이티드 Humanized Antibodies Specific to Myeloma and Ovarian Cancer Cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159764A1 (en) * 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology Method for enhancing glycoprotein stability.
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0575319B1 (en) 1991-03-11 1999-11-10 The University Of Georgia Research Foundation, Inc. Cloning and expression of renilla luciferase
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
ATE381614T1 (en) 1992-07-24 2008-01-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
AU678787B2 (en) 1992-10-23 1997-06-12 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
AU694745B2 (en) 1993-09-10 1998-07-30 Trustees Of Columbia University In The City Of New York, The Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
ES2304786T3 (en) 1995-04-27 2008-10-16 Amgen Fremont Inc. ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
WO1998026277A2 (en) 1996-12-12 1998-06-18 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1064360B1 (en) 1998-03-27 2008-03-05 Prolume, Ltd. Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159764A1 (en) * 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Anti-CHRDL1 antibody ab57933 1", 1 January 2014 (2014-01-01), XP055232972, Retrieved from the Internet <URL:http://www.abcam.com/chrdl1-antibody-ab57933.html> [retrieved on 20151202] *
B. W. LARMAN ET AL: "Chordin-like 1 and Twisted Gastrulation 1 Regulate BMP Signaling following Kidney Injury", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY., vol. 20, no. 5, 8 April 2009 (2009-04-08), US, pages 1020 - 1031, XP055232973, ISSN: 1046-6673, DOI: 10.1681/ASN.2008070768 *
UEKI TAKATOSHI ET AL: "A novel secretory factor, Neurogenesin-1, provides neurogenic environmental cues for neural stem cells in the adult hippocampus", JOURNAL OF NEUROSCIENCE, THE SOCIETY, WASHINGTON, DC, US, vol. 23, no. 37, 17 December 2003 (2003-12-17), pages 11732 - 11740, XP009179269, ISSN: 1529-2401 *

Also Published As

Publication number Publication date
WO2016040767A2 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
EA201891435A1 (en) HUMANIZED MONOCLONAL ANTIBODIES, MONOCLONAL ANTIBODIES MOUSE OR CHEMERIC MONOCLONAL ANTIBODIES AGAINST CD47
WO2017015560A3 (en) Antibody therapeutics that bind lag3
WO2016144803A8 (en) Antibody therapeutics that bind tim3
MX2022011935A (en) Antibody therapeutics that bind ctla4.
MX2017014908A (en) Trispecific binding proteins and methods of use.
EA201792221A1 (en) ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
WO2017193032A3 (en) Bispecific binding proteins and uses thereof
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
WO2016141328A3 (en) Antibody therapeutics that bind cd47
WO2016065323A3 (en) Single domain antibodies directed against intracellular antigens
WO2015112886A3 (en) Binding proteins and methods of use thereof
EA201790342A1 (en) ANTIBODIES TO TREM2 AND METHODS OF THEIR APPLICATION
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
PH12019500571A1 (en) Anti-pd-1 antibodies
WO2016164657A3 (en) Antibody therapeutics that bind cd123
WO2015161267A3 (en) Humanized and chimeric monoclonal antibodies to cd99
WO2016193872A3 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
WO2015184403A3 (en) Anti-epidermal growth factor receptor (egfr) antibodies
WO2018069871A3 (en) Anti-kras binding proteins
PH12017500332A1 (en) Antigen binding proteins that bind cxcr3
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
MA39847A (en) Antigen binding proteins that bind wisp1
WO2015117088A3 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
WO2017019957A3 (en) Binding proteins and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15767043

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15767043

Country of ref document: EP

Kind code of ref document: A2